|
1
|
Quigley HA: Open-angle glaucoma. N Engl J
Med. 328:1097–1106. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Johnson M: ‘What controls aqueous humour
outflow resistance?’. Exp Eye Res. 82:545–557. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Johnstone MA and Grant WG:
Pressure-dependent changes in structures of the aqueous outflow
system of human and monkey eyes. Am J Ophthalmol. 75:365–383. 1973.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Knepper PA, Goossens W, Hvizd M and
Palmberg PF: Glycosaminoglycans of the human trabecular meshwork in
primary open-angle glaucoma. Invest Ophthalmol Vis Sci.
37:1360–1367. 1996.
|
|
5
|
Mao W, Millar JC, Wang WH, Silverman SM,
Liu Y, Wordinger RJ, Rubin JS, Pang IH and Clark AF: Existence of
the canonical Wnt signaling pathway in the human trabecular
meshwork. Invest Ophthalmol Vis Sci. 53:7043–7051. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miller E, Yang J, DeRan M, Wu C, Su AI,
Bonamy GM, Liu J, Peters EC and Wu X: Identification of
serum-derived sphin-gosine-1-phosphate as a small molecule
regulator of YAP. Chem Biol. 19:955–962. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fleenor DL, Shepard AR, Hellberg PE,
Jacobson N, Pang IH and Clark AF: TGFbeta2-induced changes in human
trabecular meshwork: implications for intraocular pressure. Invest
Ophthalmol Vis Sci. 47:226–234. 2006. View Article : Google Scholar
|
|
8
|
Varelas X, Miller BW, Sopko R, Song S,
Gregorieff A, Fellouse FA, Sakuma R, Pawson T, Hunziker W, McNeill
H, et al: The Hippo pathway regulates Wnt/beta-catenin signaling.
Dev Cell. 18:579–591. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Varelas X, Samavarchi-Tehrani P, Narimatsu
M, Weiss A, Cockburn K, Larsen BG, Rossant J and Wrana JL: The
Crumbs complex couples cell density sensing to Hippo-dependent
control of the TGF-β-SMAD pathway. Dev Cell. 19:831–844. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kango-Singh M and Singh A: Regulation of
organ size: insights from the Drosophila Hippo signaling pathway.
Dev Dyn. 238:1627–1637. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saucedo LJ and Edgar BA: Filling out the
Hippo pathway. Nat Rev Mol Cell Biol. 8:613–621. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Buttitta LA and Edgar BA: How size is
controlled: from Hippos to Yorkies. Nat Cell Biol. 9:1225–1227.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pan D: Hippo signaling in organ size
control. Genes Dev. 21:886–897. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao B, Lei QY and Guan KL: The Hippo-YAP
pathway: new connections between regulation of organ size and
cancer. Curr Opin Cell Biol. 20:638–646. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu FX and Guan KL: The Hippo pathway:
regulators and regulations. Genes Dev. 27:355–371. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Justice RW, Zilian O, Woods DF, Noll M and
Bryant PJ: The Drosophila tumor suppressor gene warts encodes a
homolog of human myotonic dystrophy kinase and is required for the
control of cell shape and proliferation. Genes Dev. 9:534–546.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tapon N, Harvey KF, Bell DW, Wahrer DC,
Schiripo TA, Haber D and Hariharan IK: Salvador promotes both cell
cycle exit and apoptosis in Drosophila and is mutated in human
cancer cell lines. Cell. 110:467–478. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Udan RS, Kango-Singh M, Nolo R, Tao C and
Halder G: Hippo promotes proliferation arrest and apoptosis in the
Salvador/Warts pathway. Nat Cell Biol. 5:914–920. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lai ZC, Wei X, Shimizu T, Ramos E,
Rohrbaugh M, Nikolaidis N, Ho LL and Li Y: Control of cell
proliferation and apoptosis by mob as tumor suppressor, mats. Cell.
120:675–685. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang J, Wu S, Barrera J, Matthews K and
Pan D: The Hippo signaling pathway coordinately regulates cell
proliferation and apoptosis by inactivating Yorkie, the Drosophila
homolog of YAP. Cell. 122:421–434. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goulev Y, Fauny JD, Gonzalez-Marti B,
Flagiello D, Silber J and Zider A: SCALLOPED interacts with YORKIE,
the nuclear effector of the hippo tumor-suppressor pathway in
Drosophila. Curr Biol. 18:435–441. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu
J, Lin JD, Wang CY, Chinnaiyan AM, et al: TEAD mediates
YAP-dependent gene induction and growth control. Genes Dev.
22:1962–1971. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hilman D and Gat U: The evolutionary
history of YAP and the hippo/YAP pathway. Mol Biol Evol.
28:2403–2417. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao B, Li L and Guan KL: Hippo signaling
at a glance. J Cell Sci. 123:4001–4006. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rauskolb C, Pan G, Reddy BV, Oh H and
Irvine KD: Zyxin links fat signaling to the hippo pathway. PLoS
Biol. 9:e10006242011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bryant PJ, Huettner B, Held LI Jr, Ryerse
J and Szidonya J: Mutations at the fat locus interfere with cell
proliferation control and epithelial morphogenesis in Drosophila.
Dev Biol. 129:541–554. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Poernbacher I, Baumgartner R, Marada SK,
Edwards K and Stocker H: Drosophila Pez acts in Hippo signaling to
restrict intestinal stem cell proliferation. Curr Biol. 22:389–396.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hamaratoglu F, Willecke M, Kango-Singh M,
Nolo R, Hyun E, Tao C, Jafar-Nejad H and Halder G: The
tumour-suppressor genes NF2/Merlin and Expanded act through Hippo
signalling to regulate cell proliferation and apoptosis. Nat Cell
Biol. 8:27–36. 2006. View Article : Google Scholar
|
|
29
|
Zhao B, Tumaneng K and Guan KL: The Hippo
pathway in organ size control, tissue regeneration and stem cell
self-renewal. Nat Cell Biol. 13:877–883. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu J, Zheng Y, Dong J, Klusza S, Deng WM
and Pan D: Kibra functions as a tumor suppressor protein that
regulates Hippo signaling in conjunction with Merlin and Expanded.
Dev Cell. 18:288–299. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Harvey KF, Zhang X and Thomas DM: The
Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Robinson BS, Huang J, Hong Y and Moberg
KH: Crumbs regulates Salvador/Warts/Hippo signaling in Drosophila
via the FERM-domain protein Expanded. Curr Biol. 20:582–590. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Meng Z, Moroishi T and Guan KL: Mechanisms
of Hippo pathway regulation. Genes Dev. 30:1–7. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun S and Irvine KD: Cellular organization
and cytoskeletal regulation of the Hippo signaling network. Trends
Cell Biol. 26:694–704. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tyler DM and Baker NE: Expanded and fat
regulate growth and differentiation in the Drosophila eye through
multiple signaling pathways. Dev Biol. 305:187–201. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Willecke M, Hamaratoglu F, Kango-Singh M,
Udan R, Chen CL, Tao C, Zhang X and Halder G: The fat cadherin acts
through the Hippo tumor-suppressor pathway to regulate tissue size.
Curr Biol. 16:2090–2100. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
McCartney BM, Kulikauskas RM, LaJeunesse
DR and Fehon RG: The neurofibromatosis-2 homologue, Merlin, and the
tumor suppressor expanded function together in Drosophila to
regulate cell proliferation and differentiation. Development.
127:1315–1324. 2000.PubMed/NCBI
|
|
38
|
Baumgartner R, Poernbacher I, Buser N,
Hafen E and Stocker H: The WW domain protein Kibra acts upstream of
Hippo in Drosophila. Dev Cell. 18:309–316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tikoo A, Varga M, Ramesh V, Gusella J and
Maruta H: An anti-Ras function of neurofibromatosis type 2 gene
product (NF2/Merlin). J Biol Chem. 269:23387–23390. 1994.PubMed/NCBI
|
|
40
|
Yi C and Kissil JL: Merlin in organ size
control and tumorigenesis: Hippo versus EGFR? Genes Dev.
24:1673–1679. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen CL, Gajewski KM, Hamaratoglu F,
Bossuyt W, Sansores-Garcia L, Tao C and Halder G: The apical-basal
cell polarity determinant Crumbs regulates Hippo signaling in
Drosophila. Proc Natl Acad Sci USA. 107:15810–15815. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Edgar BA: From cell structure to
transcription: Hippo forges a new path. Cell. 124:267–273. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Avruch J, Zhou D, Fitamant J and Bardeesy
N: Mst1/2 signalling to Yap: gatekeeper for liver size and tumour
development. Br J Cancer. 104:24–32. 2011. View Article : Google Scholar :
|
|
44
|
Wu S, Huang J, Dong J and Pan D: Hippo
encodes a Ste-20 family protein kinase that restricts cell
proliferation and promotes apoptosis in conjunction with salvador
and warts. Cell. 114:445–456. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chan EH, Nousiainen M, Chalamalasetty RB,
Schäfer A, Nigg EA and Silljé HH: The Ste20-like kinase Mst2
activates the human large tumor suppressor kinase Lats1. Oncogene.
24:2076–2086. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Callus BA, Verhagen AM and Vaux DL:
Association of mammalian sterile twenty kinases, Mst1 and Mst2,
with hSalvador via C-terminal coiled-coil domains, leads to its
stabilization and phosphorylation. FEBS J. 273:4264–4276. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li Y, Pei J, Xia H, Ke H, Wang H and Tao
W: Lats2, a putative tumor suppressor, inhibits G1/S transition.
Oncogene. 22:4398–4405. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xia H, Qi H, Li Y, Pei J, Barton J,
Blackstad M, Xu T and Tao W: LATS1 tumor suppressor regulates G2/M
transition and apoptosis. Oncogene. 21:1233–1241. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yang X, Li DM, Chen W and Xu T: Human
homologue of Drosophila lats, LATS1, negatively regulate growth by
inducing G(2)/M arrest or apoptosis. Oncogene. 20:6516–6523. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pan D: The Hippo signaling pathway in
development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhao B, Li L, Lei Q and Guan KL: The
Hippo-YAP pathway in organ size control and tumorigenesis: an
updated version. Genes De. 24:862–874. 2010. View Article : Google Scholar
|
|
52
|
Zhang X, George J, Deb S, Degoutin JL,
Takano EA, Fox SB, Bowtell DD and Harvey KF; AOC S Study group: The
Hippo pathway transcriptional co-activator, YAP, is an ovarian
cancer oncogene. Oncogene. 30:2810–2822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sudol M: Yes-associated protein (YAP65) is
a proline-rich phosphoprotein that binds to the SH3 domain of the
Yes proto-oncogene product. Oncogene. 9:2145–2152. 1994.PubMed/NCBI
|
|
54
|
Dong J, Feldmann G, Huang J, Wu S, Zhang
N, Comerford SA, Gayyed MF, Anders RA, Maitra A and Pan D:
Elucidation of a universal size-control mechanism in Drosophila and
mammals. Cell. 130:1120–1133. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zender L, Spector MS, Xue W, Flemming P,
Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, et
al: Identification and validation of oncogenes in liver cancer
using an integrative oncogenomic approach. Cell. 125:1253–1267.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Overholtzer M, Zhang J, Smolen GA, Muir B,
Li W, Sgroi DC, Deng CX, Brugge JS and Haber DA: Transforming
properties of YAP, a candidate oncogene on the chromosome 11q22
amplicon. Proc Natl Acad Sci USA. 103:12405–12410. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chen L, Chan SW, Zhang X, Walsh M, Lim CJ,
Hong W and Song H: Structural basis of YAP recognition by TEAD4 in
the Hippo pathway. Genes Dev. 24:290–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Oh H and Irvine KD: In vivo regulation of
Yorkie phosphorylation and localization. Development.
135:1081–1088. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Oh H and Irvine KD: Yorkie: the final
destination of Hippo signaling. Trends Cell Biol. 20:410–417. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim
J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP
oncoprotein by the Hippo pathway is involved in cell contact
inhibition and tissue growth control. Genes Dev. 21:2747–2761.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kanai F, Marignani PA, Sarbassova D, Yagi
R, Hall RA, Donowitz M, Hisaminato A, Fujiwara T, Ito Y, Cantley
LC, et al: TAZ: a novel transcriptional co-activator regulated by
interactions with 14-3-3 and PDZ domain proteins. EMBO J.
19:6778–6791. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yaffe MB, Rittinger K, Volinia S, Caron
PR, Aitken A, Leffers H, Gamblin SJ, Smerdon SJ and Cantley LC: The
structural basis for 14-3-3:phosphopeptide binding specificity.
Cell. 91:961–971. 1997. View Article : Google Scholar
|
|
63
|
Lei QY, Zhang H, Zhao B, Zha ZY, Bai F,
Pei XH, Zhao S, Xiong Y and Guan KL: TAZ promotes cell
proliferation and epithelial-mesenchymal transition and is
inhibited by the Hippo pathway. Mol Cell Biol. 28:2426–2436. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Basu S, Totty NF, Irwin MS, Sudol M and
Downward J: Akt phosphorylates the Yes-associated protein, YAP, to
induce interaction with 14-3-3 and attenuation of p73-mediated
apoptosis. Mol Cell. 11:11–23. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhao B, Li L, Tumaneng K, Wang CY and Guan
KL: A coordinated phosphorylation by Lats and CK1 regulates YAP
stability through SCF(beta-TRCP). Genes Dev. 24:72–85. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Liu CY, Zha ZY, Zhou X, Zhang H, Huang W,
Zhao D, Li T, Chan SW, Lim CJ, Hong W, et al: The Hippo tumor
pathway promotes TAZ degradation by phosphorylating a phosphodegron
and recruiting the SCF{beta}-TrCP E3 ligase. J Biol Chem.
285:37159–37169. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Camargo FD, Gokhale S, Johnnidis JB, Fu D,
Bell GW, Jaenisch R and Brummelkamp TR: YAP1 increases organ size
and expands undifferentiated progenitor cells. Curr Biol.
17:2054–2060. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Da CL, Xin Y, Zhao J and Luo XD:
Significance and relationship between Yes-associated protein and
survivin expression in gastric carcinoma and precancerous lesions.
World J Gastroenterol. 15:4055–4061. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Wang X, Su L and Ou Q: Yes-associated
protein promotes tumour development in luminal epithelial derived
breast cancer. Eur J Cancer. 48:1227–1234. 2012. View Article : Google Scholar
|
|
70
|
Lam-Himlin DM, Daniels JA, Gayyed MF, Dong
J, Maitra A, Pan D, Montgomery EA and Anders RA: The Hippo pathway
in human upper gastrointestinal dysplasia and carcinoma: a novel
oncogenic pathway. Int J Gastrointest Cancer. 37:103–109. 2006.
|
|
71
|
Wada K, Itoga K, Okano T, Yonemura S and
Sasaki H: Hippo pathway regulation by cell morphology and stress
fibers. Development. 138:3907–3914. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Straßburger K, Tiebe M, Pinna F, Breuhahn
K and Teleman AA: Insulin/IGF signaling drives cell proliferation
in part via Yorkie/YAP. Dev Biol. 367:187–196. 2012. View Article : Google Scholar
|
|
73
|
Yu FX, Zhao B, Panupinthu N, Jewell JL,
Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H, et al:
Regulation of the Hippo-YAP pathway by G-protein-coupled receptor
signaling. Cell. 150:780–791. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Fan R, Kim NG and Gumbiner BM: Regulation
of Hippo pathway by mitogenic growth factors via phosphoinositide
3-kinase and phosphoinositide-dependent kinase-1. Proc Natl Acad
Sci USA. 110:2569–2574. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Kikuchi A, Yamamoto H and Sato A:
Selective activation mechanisms of Wnt signaling pathways. Trends
Cell Biol. 19:119–129. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
He X, Semenov M, Tamai K and Zeng X: LDL
receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling:
arrows point the way. Development. 131:1663–1677. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Hoffmeyer K, Raggioli A, Rudloff S, Anton
R, Hierholzer A, Del Valle I, Hein K, Vogt R and Kemler R:
Wnt/β-catenin signaling regulates telomerase in stem cells and
cancer cells. Science. 336:1549–1554. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Ouyang H, Zhuo Y and Zhang K: WNT
signaling in stem cell differentiation and tumor formation. J Clin
Invest. 123:1422–1424. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Xing Y, Clements WK, Kimelman D and Xu W:
Crystal structure of a beta-catenin/axin complex suggests a
mechanism for the beta-catenin destruction complex. Genes Dev.
17:2753–2764. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Habas R and Dawid IB: Dishevelled and Wnt
signaling: is the nucleus the final frontier? J Biol. 4:22005.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Tolwinski NS, Wehrli M, Rives A, Erdeniz
N, DiNardo S and Wieschaus E: Wg/Wnt signal can be transmitted
through arrow/LRP5,6 and Axin independently of Zw3/Gsk3beta
activity. Dev Cell. 4:407–418. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa
N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, et al:
AXIN1 mutations in hepatocellular carcinomas, and growth
suppression in cancer cells by virus-mediated transfer of AXIN1.
Nat Genet. 24:245–250. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
84
|
Giles RH, van Es JH and Clevers H: Caught
up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta.
1653:1–24. 2003.PubMed/NCBI
|
|
85
|
Cong F, Schweizer L and Varmus H: Wnt
signals across the plasma membrane to activate the beta-catenin
pathway by forming oligomers containing its receptors, Frizzled and
LRP. Development. 131:5103–5115. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Cliffe A, Hamada F and Bienz M: A role of
Dishevelled in relocating Axin to the plasma membrane during
wingless signaling. Curr Biol. 13:960–966. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Saito-Diaz K, Chen TW, Wang X, Thorne CA,
Wallace HA, Page-McCaw A and Lee E: The way Wnt works: components
and mechanism. Growth Factors. 31:1–31. 2013. View Article : Google Scholar :
|
|
88
|
Gan XQ, Wang JY, Xi Y, Wu ZL, Li YP and Li
L: Nuclear Dvl, c-Jun, beta-catenin, and TCF form a complex leading
to stabilization of beta-catenin-TCF interaction. J Cell Biol.
180:1087–1100. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Itoh K, Brott BK, Bae GU, Ratcliffe MJ and
Sokol SY: Nuclear localization is required for Dishevelled function
in Wnt/beta-catenin signaling. J Biol. 4:32005. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Azzolin L, Zanconato F, Bresolin S,
Forcato M, Basso G, Bicciato S, Cordenonsi M and Piccolo S: Role of
TAZ as mediator of Wnt signaling. Cell. 151:1443–1456. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Heallen T, Zhang M, Wang J,
Bonilla-Claudio M, Klysik E, Johnson RL and Martin JF: Hippo
pathway inhibits Wnt signaling to restrain cardiomyocyte
proliferation and heart size. Science. 332:458–461. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Willert K, Shibamoto S and Nusse R:
Wnt-induced dephosphorylation of axin releases beta-catenin from
the axin complex. Genes Dev. 13:1768–1773. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Li VS, Ng SS, Boersema PJ, Low TY,
Karthaus WR, Gerlach JP, Mohammed S, Heck AJ, Maurice MM, Mahmoudi
T, et al: Wnt signaling through inhibition of β-catenin degradation
in an intact Axin1 complex. Cell. 149:1245–1256. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Konsavage WM Jr, Kyler SL, Rennoll SA, Jin
G and Yochum GS: Wnt/β-catenin signaling regulates Yes-associated
protein (YAP) gene expression in colorectal carcinoma cells. J Biol
Chem. 287:11730–11739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Azzolin L, Panciera T, Soligo S, Enzo E,
Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, Guzzardo V,
et al: YAP/TAZ incorporation in the β-catenin destruction complex
orchestrates the Wnt response. Cell. 158:157–170. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Wang WH, McNatt LG, Pang IH, Millar JC,
Hellberg PE, Hellberg MH, Steely HT, Rubin JS, Fingert JH,
Sheffield VC, et al: Increased expression of the WNT antagonist
sFRP-1 in glaucoma elevates intraocular pressure. J Clin Invest.
118:1056–1064. 2008.PubMed/NCBI
|
|
97
|
Morgan JT, Raghunathan VK, Chang YR,
Murphy CJ and Russell P: Wnt inhibition induces persistent
increases in intrinsic stiffness of human trabecular meshwork
cells. Exp Eye Res. 132:174–178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Kwon HS, Lee HS, Ji Y, Rubin JS and
Tomarev SI: Myocilin is a modulator of Wnt signaling. Mol Cell
Biol. 29:2139–2154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Tovar-Vidales T, Roque R, Clark AF and
Wordinger RJ: Tissue transglutaminase expression and activity in
normal and glaucomatous human trabecular meshwork cells and
tissues. Invest Ophthalmol Vis Sci. 49:622–628. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Choi JW, Herr DR, Noguchi K, Yung YC, Lee
CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN, et al: LPA
receptors: subtypes and biological actions. Annu Rev Pharmacol
Toxicol. 50:157–186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
van Corven EJ, Groenink A, Jalink K,
Eichholtz T and Moolenaar WH: Lysophosphatidate-induced cell
proliferation: identification and dissection of signaling pathways
mediated by G proteins. Cell. 59:45–54. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Shida D, Kitayama J, Yamaguchi H, Okaji Y,
Tsuno NH, Watanabe T, Takuwa Y and Nagawa H: Lysophosphatidic acid
(LPA) enhances the metastatic potential of human colon carcinoma
DLD1 cells through LPA1. Cancer Res. 63:1706–1711. 2003.PubMed/NCBI
|
|
103
|
Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W,
Zhang F, Yu S, Stephens LC, Cui X, Murrow G, et al: Expression of
autotaxin and lysophosphatidic acid receptors increases mammary
tumorigenesis, invasion, and metastases. Cancer Cell. 15:539–550.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Rohen JW: Why is intraocular pressure
elevated in chronic simple glaucoma? Anatomical considerations.
Ophthalmology. 90:758–765. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
No authors listed. The Advanced Glaucoma
Intervention Study (AGIS): 7. The relationship between control of
intraocular pressure and visual field deterioration. The AGIS
Investigators. Am J Ophthalmol. 130:429–440. 2000. View Article : Google Scholar
|
|
106
|
Gasiorowski JZ and Russell P: Biological
properties of trabecular meshwork cells. Exp Eye Res. 88:671–675.
2009. View Article : Google Scholar
|
|
107
|
Iyer P, Lalane R III, Morris C, Challa P,
Vann R and Rao PV: Autotaxin-lysophosphatidic acid axis is a novel
molecular target for lowering intraocular pressure. PLoS One.
7:e426272012. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Li AF, Tane N and Roy S: Fibronectin
overexpression inhibits trabecular meshwork cell monolayer
permeability. Mol Vis. 10:750–757. 2004.PubMed/NCBI
|
|
109
|
Willier S, Butt E and Grunewald TG:
Lysophosphatidic acid (LPA) signalling in cell migration and cancer
invasion: a focussed review and analysis of LPA receptor gene
expression on the basis of more than 1700 cancer microarrays. Biol
Cell. 105:317–333. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
De Larco JE and Todaro GJ: Growth factors
from murine sarcoma virus-transformed cells. Proc Natl Acad Sci
USA. 75:4001–4005. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Todaro GJ and De Larco JE: Growth factors
produced by sarcoma virus-transformed cells. Cancer Res.
38:4147–4154. 1978.PubMed/NCBI
|
|
112
|
Roberts AB, Lamb LC, Newton DL, Sporn MB,
De Larco JE and Todaro GJ: Transforming growth factors: isolation
of polypeptides from virally and chemically transformed cells by
acid/ethanol extraction. Proc Natl Acad Sci USA. 77:3494–3498.
1980. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Pena RA, Jerdan JA and Glaser BM: Effects
of TGF-beta and TGF-beta neutralizing antibodies on
fibroblast-induced collagen gel contraction: implications for
proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci.
35:2804–2808. 1994.PubMed/NCBI
|
|
114
|
Border WA, Noble NA, Yamamoto T, Harper
JR, Yamaguchi Yu, Pierschbacher MD and Ruoslahti E: Natural
inhibitor of transforming growth factor-beta protects against
scarring in experimental kidney disease. Nature. 360:361–364. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Zode GS, Sethi A, Brun-Zinkernagel AM,
Chang IF, Clark AF and Wordinger RJ: Transforming growth factor-β2
increases extracellular matrix proteins in optic nerve head cells
via activation of the Smad signaling pathway. Mol Vis.
17:1745–1758. 2011.
|
|
116
|
Itoh S, Itoh F, Goumans MJ and Ten Dijke
P: Signaling of transforming growth factor-beta family members
through Smad proteins. Eur J Biochem. 267:6954–6967. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Dupont J, McNeilly J, Vaiman A, Canepa S,
Combarnous Y and Taragnat C: Activin signaling pathways in ovine
pituitary and LbetaT2 gonadotrope cells. Biol Reprod. 68:1877–1887.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Chen HB, Shen J, Ip YT and Xu L:
Identification of phosphatases for Smad in the BMP/DPP pathway.
Genes Dev. 20:648–653. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Eisenstein R and Grant-Bertacchini D:
Growth inhibitory activities in avascular tissues are recognized by
anti-transforming growth factor beta antibodies. Curr Eye Res.
10:157–162. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Tripathi RC, Li J, Chan WF and Tripathi
BJ: Aqueous humor in glaucomatous eyes contains an increased level
of TGF-beta 2. Exp Eye Res. 59:723–727. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Inatani M, Tanihara H, Katsuta H, Honjo M,
Kido N and Honda Y: Transforming growth factor-beta 2 levels in
aqueous humor of glaucomatous eyes. Graefes Arch Clin Exp
Ophthalmol. 239:109–113. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Pervan CL, Lautz JD, Blitzer AL, Langert
KA and Stubbs EB Jr: Rho GTPase signaling promotes constitutive
expression and release of TGF-β2 by human trabecular meshwork
cells. Exp Eye Res. 146:95–102. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Rao PV, Deng PF, Kumar J and Epstein DL:
Modulation of aqueous humor outflow facility by the Rho
kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci.
42:1029–1037. 2001.PubMed/NCBI
|
|
124
|
Inoue T and Tanihara H: Rho-associated
kinase inhibitors: a novel glaucoma therapy. Prog Retin Eye Res.
37:1–12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Takai Y, Tanito M and Ohira A: Multiplex
cytokine analysis of aqueous humor in eyes with primary open-angle
glaucoma, exfoliation glaucoma, and cataract. Invest Ophthalmol Vis
Sci. 53:241–247. 2012. View Article : Google Scholar
|
|
126
|
Li J, Tripathi BJ and Tripathi RC:
Modulation of pre-mRNA splicing and protein production of
fibronectin by TGF-beta2 in porcine trabecular cells. Invest
Ophthalmol Vis Sci. 41:3437–3443. 2000.PubMed/NCBI
|
|
127
|
Wordinger RJ, Clark AF, Agarwal R, Lambert
W, McNatt L, Wilson SE, Qu Z and Fung BK: Cultured human trabecular
meshwork cells express functional growth factor receptors. Invest
Ophthalmol Vis Sci. 39:1575–1589. 1998.PubMed/NCBI
|
|
128
|
Tamm ER, Siegner A, Baur A and
Lütjen-Drecoll E: Transforming growth factor-beta 1 induces
alpha-smooth muscle-actin expression in cultured human and monkey
trabecular meshwork. Exp Eye Res. 62:389–397. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Varelas X, Sakuma R, Samavarchi-Tehrani P,
Peerani R, Rao BM, Dembowy J, Yaffe MB, Zandstra PW and Wrana JL:
TAZ controls Smad nucleocytoplasmic shuttling and regulates human
embryonic stem-cell self-renewal. Nat Cell Biol. 10:837–848. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Quigley HA and Broman AT: The number of
people with glaucoma worldwide in 2010-2020. Br J Ophthalmol.
90:262–267. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Tamm ER: The trabecular meshwork outflow
pathways: structural and functional aspects. Exp Eye Res.
88:648–655. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Last JA, Pan T, Ding Y, Reilly CM, Keller
K, Acott TS, Fautsch MP, Murphy CJ and Russell P: Elastic modulus
determination of normal and glaucomatous human trabecular meshwork.
Invest Ophthalmol Vis Sci. 52:2147–2152. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Dupont S, Morsut L, Aragona M, Enzo E,
Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M,
Bicciato S, et al: Role of YAP/TAZ in mechanotransduction. Nature.
474:179–183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Raghunathan VK, Morgan JT, Dreier B,
Reilly CM, Thomasy SM, Wood JA, Ly I, Tuyen BC, Hughbanks M, Murphy
CJ, et al: Role of substratum stiffness in modulating genes
associated with extracellular matrix and mechanotransducers YAP and
TAZ. Invest Ophthalmol Vis Sci. 54:378–386. 2013. View Article : Google Scholar :
|
|
135
|
Comes N, Buie LK and Borras T: Evidence
for a role of angiopoietin-like 7 (ANGPTL7) in extracellular matrix
formation of the human trabecular meshwork: implications for
glaucoma. Genes Cells. 16:243–259. 2011. View Article : Google Scholar : PubMed/NCBI
|
